Former Lansinoh CEO shifts to Insight Pharmaceuticals
LANGHORNE, Pa. A developer, manufacturer and marketer of OTC consumer brands has appointed a new chief executive.
Insight Pharmaceuticals, maker of such brands as Anacin and Dermarest, announced that Gary Downing will become CEO of the company Feb. 15. Prior to this appointment, Downing served as CEO of breastfeeding product maker Lansinoh for nearly eight years, leading the company’s and profitability to grow more than fivefold and sevenfold, respectively. Downing also co-founded niche OTC brand marketing company Medtech, and held senior management positions at such industry leaders as Rhone-Poulene Rorer, Gillette’s Oral-B Labs and Richardson-Vicks, where he had a successful track record of developing profitable businesses.
“We are very excited to have someone of Gary’s caliber joining the Insight team and are looking forward to his leadership and contribution to further the growth of our business. His background and experience in acquiring and developing brands are a perfect complement to our long-term strategy,” said Mo Stout, Insight Pharmaceuticals chairman.
Yakult makes its way to Colorado, New Mexico
TORRANCE, Calif. A probiotic drink is making its way to the Colorado and New Mexico markets.
Yakult, a citrusy shot-sized beverage aimed to help maintain a healthy digestive system, now is available in such grocery chains as Walmart, Safeway, Albertsons and more.
“In Colorado and New Mexico we will continue to educate customers about probiotics and the importance of a healthy lifestyle, while sampling Yakult at in-store demos and community events,” said Masaaki Sunami, Yakult VP marketing and sales. “We believe that once people try our product they will understand the benefits for themselves.”
Sanofi-Aventis completes tender offer for Chattem
PARIS A leading global pharmaceutical company has successfully completed its tender offer for all outstanding shares of common stock of a consumer healthcare products manufacturer.
Sanofi-Aventis’ tender offer and withdrawal rights expired for Chattem expired Monday. All shares were validly tendered and have been accepted for purchase at the offer price of $93.50 per share.
The drug maker announced in January its tender offer for Chattem, maker of such products as Gold Bond and Selsun Blue. Sanofi-Aventis first expressed interest in Chattem Dec. 20.